Figure 2From: Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study Prevalence of NAbs according to the clinical response. Within the groups of patients showing poor clinical response (Group A and B), only 16 out of 94 patients (17.0%) are NAb-positive and 78 (83%) are NAb-negative. This suggests that NAbs presence explains only partially the poor clinical response to IFNβ.Back to article page